Hand, foot and mouth disease (HFMD) was first reported in New Zealand in 1957 and occurs mostly in young children, with a peak incidence at about 2 years of age. The causative agents of HFMD are picornaviruses, most often of human enterovirus species A, chiefly the Coxsackie A viruses and Enterovirus A71 (EV71). To date three vaccines against EV71 have been licensed in China, all using C4 genogroup strains. The efficacy of these three vaccines after two doses immunization ranges from 90.0% to 97.4% after one year of surveillance to 95.1% after two-year follow-up. Candidate vaccines containing B4 and B5 genogroups are in development elsewhere but have not yet reached the licensing stage. Other vaccines such as recombinant and other forms of subunit vaccines, vectored vaccines, virus-like particle vaccines are in the early stage of development. In addition, the development of vaccines against Coxsackie A16, A6 and A10 is being considered with a view to developing combination/multivalent vaccines

Market Analysis and Insights: Global and Japan Enterovirus Vaccine Market
This report focuses on global and Japan Enterovirus Vaccine market.
In 2020, the global Enterovirus Vaccine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Enterovirus Vaccine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Enterovirus Vaccine Scope and Market Size
Enterovirus Vaccine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Enterovirus Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Enterovirus Vaccine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
Coxasckievirus A
Coxasckievirus B
Human Enterovirus 71
Others

Segment by Application
Hospital
Research Institute
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Sinovac Biotech
Medigen Vaccine Biologics
Shenzhen Neptunus
Sinopharm
Adimmune
Intravacc
Shanghai Zerun Biotechnology
Beijing Minhai Biotechnology